Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The complex interaction between dengue viruses and the human immune system means that development of a safe, effective dengue vaccine was never going to be simple. The only currently licenced dengue vaccine (Dengvaxia®) does, indeed, have a complex immune profile depending on recipients' immune status, meaning that use of this vaccine is not straightforward. This commentary reviews the recommendations for vaccine use to date, and discusses issues and opportunities related to the implementation of vaccination programmes in light of these recommendations. Future dengue vaccines may also have similar profiles, so it is vital that these issues are addressed now to ensure optimal use of vaccination in the fight against dengue globally.

Original publication

DOI

10.1093/trstmh/try070

Type

Journal article

Journal

Trans R Soc Trop Med Hyg

Publication Date

01/08/2018

Volume

112

Pages

367 - 368

Keywords

Antibody-Dependent Enhancement, Dengue, Dengue Vaccines, Dengue Virus, Global Health, Humans, Immunization Programs, Patient Selection, Program Development, Serogroup, Severe Dengue, Vaccination